[SCHEDULE 13G/A] Catheter Precision, Inc. SEC Filing

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 1,120,635 shares of Catheter Precision, Inc. common stock, representing 4.99% of the class. The filing states the Reporting Persons hold shared voting and dispositive power over these shares and have no sole voting or dispositive power. Armistice is the investment manager of the Master Fund, which directly holds the shares, and the Master Fund disclaims beneficial ownership by virtue of the investment management agreement. The Reporting Persons certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control.

Positive

• Transparent disclosure of beneficial ownership and voting/dispositive powers
• Position is below 5%, signaling passive ownership rather than control intent per the certification
• Clear attribution of roles between Armistice as manager and the Master Fund as direct holder

Negative

• Shared voting power indicates Armistice can influence decisions for the Master Fundwhich may concern some investors
• Position at 4.99% is close to the 5% reporting threshold, so future accumulation could trigger different regulatory requirements

Insights

Financial Analyst

TL;DR: A sub-5% passive stake with shared control indicates a monitored position but not an immediate control play.

The reported 4.99% position is material enough for disclosure yet sits below common thresholds that trigger mandatory activist or control presumptions. Shared voting and dispositive power implies Armistice, via its management agreement, directs decisions for the holding entity rather than holding sole authority. For investors, this signals a watchable stake that could inform secondary market interest but does not constitute a controlling or majority position.

Corporate Governance Expert

TL;DR: Shared power and the manager/master fund structure require disclosure but do not alone indicate governance change intent.

The disclosure appropriately attributes voting and investment authority to Armistice as manager and notes the Master Funddisclaimer of beneficial ownership due to the management agreement. The certification that holdings are ordinary-course and not intended to influence control reduces regulatory concern. However, proximity to the 5% threshold means any additional accumulation could alter reporting obligations and market perception of potential governance intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Catheter Precision, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per shar

(Title of Class of Securities)

74933X609

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74933X609

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,120,635.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,120,635.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,120,635.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 74933X609

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,120,635.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,120,635.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,120,635.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Catheter Precision, Inc.
(b)	Address of issuer's principal executive offices: 1670 HIGHWAY 160 WEST, SUITE 205, FORT MILL, SC, 29708
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common Stock, par value $0.0001 per shar
(e)	CUSIP No.: 74933X609
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,120,635
(b)	Percent of class: 4.99 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 1,120,635
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1,120,635 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	08/14/2025

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	08/14/2025

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 15, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

How many shares does Armistice Capital report owning in VTAK?

The filing states 1,120,635 shares, representing 4.99% of Catheter Precision, Inc. common stock.

Does Armistice Capital have sole voting control of the VTAK shares?

No. The filing reports 0 sole voting power and shared voting power of 1,120,635 shares.

Who is the direct holder of the VTAK shares reported?

The direct holder is the Armistice Capital Master Fund Ltd., while Armistice Capital acts as the investment manager with voting and investment authority.

Does the filing state the stake is intended to influence control of VTAK?

No. The Reporting Persons certify the securities were acquired and are held in the ordinary course of business and not to change or influence control.

What does the Master Funddisclaimer mean for VTAK investors?

It means the Master Fund disclaims beneficial ownership of the shares because it lacks the power to vote or dispose of them under its agreement with Armistice, which may clarify where decision authority resides.